Metrics as of 10/17/2026, 09:25 AM (Berlin time), refresh in progress.
Annovis Bio Stock
Annovis Bio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Maria L. Maccecchini
- Employees
- 7
- Market cap
- $42 M
- IPO
- 29/01/2020
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also…
Annovis Bio stock: price history
1D
-5.4%
1W
-17.9%
1M
-4.5%
6M
-46.9%
YTD
-71.3%
1Y
-51.1%
2Y
-89.1%
5Y
-96.5%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~35% stronger price swings than usual
Ask the agents about Annovis Bio
Analyst assessment of Annovis Bio
PRICE TARGET LOW
US$21.00
CONSENSUS
US$25.67
MEDIAN
US$26.00
PRICE TARGET HIGH
US$30.00
0
STRONG BUY
7
BUY
2
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 28/08/2026
Annovis Bio stock metrics
P/E
-0.55
P/B
-8.76
EV/EBITDA
-0.48
RETURN ON EQUITY
348.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.2%
FLOAT SHARES
37,640,192
AVG. DAILY VOLUME (30D)
986,270
Insider transactions (SEC)
Hoffman Michael B
Hoffman Michael B
Hoffman Michael B
Institutional holders
Comparable stocks
Frequently asked questions about Annovis Bio stock
What does Annovis Bio do?
Annovis Bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Maria L. Maccecchini, the company employs around 7 people.
The IPO was on 29/01/2020; the stock trades on NYSE under the ticker ANVS.
What do analysts say about Annovis Bio stock?
9 analysts rate the stock, the consensus is Buy (as of 28/08/2026).
The average price target is US$25.67, ranging from US$21.00 to US$30.00, with a median of US$26.00.
This is an external assessment, not a statement by Market Jury.
When does Annovis Bio report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 35% stronger than usual.
Does Annovis Bio pay a dividend?
No, Annovis Bio currently does not pay a dividend.
Which stocks are comparable to Annovis Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Annovis Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Annovis Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.